Etropal AD (XBUL:ETR) Notes Receivable: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBUL:ETR Etropal AD XBUL:ETR
50 GF Score
Price €2.52
GF Value €8.63
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Etropal AD Notes Receivable?

Etropal AD XBUL:ETR 50 Notes Receivable is €0.00 Mil as of Dec. 2025. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.63 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Etropal AD's Notes Receivable for the quarter that ended in Dec. 2025 was €0.00 Mil.

Etropal AD Notes Receivable Historical Data

* Premium members only.

The historical data trend for Etropal AD's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Etropal AD Notes Receivable Chart

Etropal AD Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Etropal AD Semi-Annual Data
Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XBUL:ETR
50GF Score
Etropal AD XBUL:ETR
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Etropal AD Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Etropal AD (XBUL:ETR) has a Notes Receivable of €0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Etropal AD and its competitors.
Is Etropal AD's Notes Receivable too high?
Etropal AD's current Notes Receivable is €0.00 Mil. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's Notes Receivable compare to ISRG and BDX?
Etropal AD's Notes Receivable of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Etropal AD and its competitors. Etropal AD's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.63, compared to a current price of €2.52 — trading 70.8% below its estimated fair value. The current Notes Receivable is €0.00 Mil. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current Notes Receivable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Etropal AD (XBUL:ETR) Overvalued in 2026?

Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued. The current stock price of €2.52 is trading 70.8% below its estimated GF Value™ of €8.63. GuruFocus considers Etropal AD to be Significantly Undervalued.

Key valuation signals for XBUL:ETR:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €8.63 vs. price of €2.52 (70.8% below fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Etropal AD Business Description

Address 191 Rusky Boulevard, Etropole, Sofia, BGR, 2180
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score

Get the complete analysis for XBUL:ETR

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price
€8.63
GF Value